Blog

Bluebird’s tweaked sickle cell gene therapy clears early test – FierceBiotech


FierceBiotech

Bluebird's tweaked sickle cell gene therapy clears early test
FierceBiotech
Bluebird bio has posted early clinical data suggesting work to rescue its sickle cell gene therapy may pay off. The tweaked gene therapy triggered a jump in the proportion of vector-positive cells in the two patients treated so far, raising hopes
Bluebird marks progress on Lentiglobin gene therapyBioPharma Dive


#ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is workingEndpoints News
Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed …Business Wire (press release)
Dispatch Tribunal
all 43 news articles »

2017-11-01 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.